SCHEMBL1809442

SCHEMBL1809442

CC(=O)c1cc(C(=O)O)no1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.50
ALDH1A1 P00352 4/20 0.46
PTPN1 P18031 2/20 0.43
HPGD P15428 2/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
RARA P10276 4/20 0.37
RXRA P19793 4/20 0.37
RARG P13631 3/20 0.37
RXRG P48443 2/20 0.37
HTT P42858 1/20 0.37
RARB P10826 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
HIF1A Q16665 1/20 0.37
DAO P14920 1/20 0.36
MME P08473 1/20 0.36
KMT2A Q03164 1/20 0.36
CDH1 P12830 1/20 0.36
CTNNB1 P35222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806245 0.84 HCAR2 (0.61) HCAR2ALDH1A1PTPN1HPGDMAPT
SCHEMBL21523817 0.83 HCAR2 (0.47) HCAR2ALDH1A1PTPN1HPGDMAPT
SCHEMBL31123940 0.83 HCAR2 (0.61) HCAR2ALDH1A1PTPN1HPGDMAPT
SCHEMBL15779831 0.81 SCD5 (0.42) HCAR2ALDH1A1HPGDMAPTHTT
SCHEMBL20780873 0.81 HCAR2 (0.39) HCAR2ALDH1A1HPGDMAPTHTT
SCHEMBL3823346 0.78 ALDH1A1 (0.46) HCAR2ALDH1A1PTPN1HPGDMAPT
SCHEMBL1613078 0.76
SCHEMBL14882527 0.76
SCHEMBL14242211 0.75 HCAR2 (0.57) HCAR2ALDH1A1PTPN1HPGDMAPT
SCHEMBL10092812 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133989-A1 SMYD MODULATORS AND USES THEREOF ALT-BIO PTE. LTD. (SG) 2025-06-26 WO disclosed
US-12325702-B2 ATF6 inhibitors and uses thereof ALTOS LABS, INC. (US) 2025-06-10 US disclosed
CN-119060036-A ATF6 inhibitors and uses thereof 阿尔托斯实验室公司 2024-12-03 CN disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
CN-112313224-B ATF6 inhibitors and uses thereof 阿尔托斯实验室公司 2024-08-13 CN disclosed
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2024-04-18 US disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 US disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 US disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 EP disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 WO disclosed
EP-0879223-B1 AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS CT EUROP DE BIOPROSPECTIVE CEB (FR) 2001-11-07 EP disclosed
EP-0879223-A1 AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS Centre Europeen de Bioprospective -CEB (FR) 1998-11-25 EP disclosed
WO-1997026237-A1 AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS CENTRE EUROPEEN DE BIOPROSPECTIVE - CEB (FR) 1997-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 HCAR2 4182/4885ALDH1A1 4447/4885PTPN1 3636/4885
US-12325702-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 HCAR2 4182/4885ALDH1A1 4447/4885PTPN1 3636/4885
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 HCAR2 4182/4885ALDH1A1 4447/4885PTPN1 3636/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG HCAR2 364/4885ALDH1A1 570/4885PTPN1 1057/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG HCAR2 364/4885ALDH1A1 570/4885PTPN1 1057/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG HCAR2 364/4885ALDH1A1 570/4885PTPN1 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.